New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 6, 2014
04:55 EDTATHN, ATHN, JNJ, JNJ, CERN, CERN, UNH, UNH, SNY, SNY, PFE, PFE, MDT, MDT, CAH, CAH, BCR, BCR, AGTC, AGTCPiper Jaffray to hold a summit
3rd Annual Heartland Summit to be held in Minneapolis on August 6-7.
News For ATHN;BCR;CAH;MDT;PFE;SNY;UNH;CERN;JNJ;AGTC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
November 14, 2014
12:43 EDTMDTMedtronic readying $10B bond sale for Covidien deal, WSJ reports
Subscribe for More Information
11:50 EDTMDTMedtronic readying $10B bond sale for Covidien deal, Dow reports
Subscribe for More Information
07:14 EDTPFEAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
November 13, 2014
16:35 EDTMDTMedtronic study reveals heart rhythm disorders in patients with ESRD
Subscribe for More Information
16:28 EDTJNJGeron announces global strategic collaboration with Janssen Biotech
Geron (GERN) announced that the company has entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, a Johnson & Johnson (JNJ) company, to develop and commercialize, imetelstat, Geron's telomerase inhibitor product candidate, for oncology, including hematologic malignancies, and other human therapeutics uses. Imetelstat is a modified oligonucleotide that is currently in early phase clinical development for myelofibrosis, or MF, and may have activity in other hematologic myeloid malignancies such as myelodysplastic syndrome, or MDS, and acute myelogenous leukemia, or AML. Under the terms of the agreement, Geron will receive an initial payment of $35M due after the applicable waiting periods under the Hart-Scott Rodino Act and is eligible to receive additional payments up to a potential total of $900M for the achievement of development, regulatory and commercial milestones, as well as royalties on worldwide net sales. Certain regulatory, development, manufacturing and promotional activities will be managed through a joint governance structure, with Janssen responsible for operational implementation of these activities. All sales will be booked by Janssen.
14:50 EDTMDTLonestar Capital to shut down by mid-2015, WSJ reports
Subscribe for More Information
14:45 EDTMDTLonestar capital to shut down, DJ reports
Subscribe for More Information
13:27 EDTMDTMedtronic likely to continue to make new highs, Barron's says
Subscribe for More Information
11:54 EDTJNJJanssen announces FDA approved sNDA for INVEGA SUSTENNA
Subscribe for More Information
10:44 EDTJNJMallinckrodt news on generic Concerta positive for Actavis, says BMO Capital
Subscribe for More Information
09:19 EDTAGTCApplied Genetic price target raised to $34 from $25 at Roth Capital
Roth Capital increased its price target on Applied Genetic as the firm is encouraged by what it sees as the continued progress of the company's clinical program, and by the company's efforts to expand its pipeline. The firm expects the company to report important data catalysts in 2015 and reiterates a Buy rating.
07:40 EDTSNYSanofi investor meeting timing tough in light of CEO ouster, Reuters says
Subscribe for More Information
07:38 EDTPFEBloomberg Link to hold a conference
The Year Ahead: 2015 is being held in Washington, D.C. with a pre-conference dinner on November 13 followed by company presentations on November 14,
07:02 EDTAGTCApplied Genetic price target raised to $28 from $24 at Cantor
Subscribe for More Information
November 12, 2014
16:14 EDTAGTCApplied Genetic reports Q1 EPS (34c), consensus (29c)
Reports Q1 revenue $705K, consensus $270K.
11:17 EDTPFELeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
08:13 EDTSNY, PFEBoston Biotech to hold a conference
Subscribe for More Information
08:02 EDTPFE, CERNCredit Suisse to hold a conference
Subscribe for More Information
07:31 EDTUNHUnitedHealth announces formation of office of the CEO
Subscribe for More Information
07:23 EDTMDTMedtronic volatility elevated into Q2 and outlook
Medtronic November call option implied volatility is at 23, December is at 20, January is at 19, February is at 18; compared to its 26-week average of 19 according to Track Data, suggesting large near term price movement into the expected release of Q2 results on November 18.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use